Psychometric Properties of Patient-Reported Outcome Measures Assessing Shoulder Function in Athletes: A Systematic Review.

Musculoskeletal CareSep 1, 2026
Clinical ResearchPhysical Medicine & RehabilitationOrthopedic Surgery

Eleftherios Paraskevopoulos, George M Pamboris, Kyriakos Pavlou et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the psychometric properties of athlete-specific patient-reported outcome measures (PROMs) for shoulder function in sports. It included 20 studies, revealing that the KJOC and FAST PROMs demonstrated good-to-excellent reliability (ICC = 0.88-0.97) and strong construct validity. Responsiveness was best for FAST and SSV-Sport, highlighting the need for further validation in translations.

Key findings

  • Reliability of PROMs ranged from good to excellent, with ICC values between 0.88 and 0.97.
  • Construct validity was strongest for the KJOC and FAST measures.
  • FAST and SSV-Sport showed the best responsiveness among the evaluated PROMs.
  • Single-item PROMs demonstrated feasibility but had narrower construct coverage and ceiling effects.

Why it matters

Understanding the psychometric properties of shoulder PROMs is crucial for clinicians to accurately assess and monitor shoulder function in athletes, ensuring effective treatment and rehabilitation strategies.

Source

PubMed · PMID 42420771

Published in Musculoskeletal Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Physical Medicine & Rehabilitation

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.